Virogin is dedicated to bringing next generation immuno-oncolytic therapeutics to the clinic through our robust pipeline.

Our lead asset, VG161, has completed the IND-enabling phase, in preparation for clinical development. The programs in our broader Synerlytic™ platform serve as the backbone of Virogin’s continued R&D of targeted and improved cancer therapeutics.